Skip CCR Main Navigation National Cancer Institute National Cancer Institute U.S. National Institutes of Health
CCR - For Our Staff| Home |

Our Science – Lee Website

Jung-Min Lee, M.D.

Selected Publications

1)  Moon DH, Lee J, Noonan AM, Annunziata CM, Minasian L, Houston N, Hays JL, Kohn EC.
Deleterious BRCA1/2 mutation is an independent risk factor for carboplatin hypersensitivity reactions.
Br. J. Cancer. 109: 1072-8, 2013.
2)  Lee JM, Hays JL, Noonan AM, Squires J, Minasian L, Annunziata C, Wood BJ, Yu M, Calvo KR, Houston N, Azad N, Kohn EC.
Feasibility and safety of sequential research-related tumor core biopsies in clinical trials.
Cancer. 119: 1357-64, 2013.
3)  Lee JM, Han JJ, Altwerger G, Kohn EC.
Proteomics and biomarkers in clinical trials for drug development.
J Proteomics. 74: 2632-41, 2011.
4)  O'Sullivan CC, Moon DH, Kohn EC, Lee JM.
Beyond Breast and Ovarian Cancers: PARP Inhibitors for BRCA Mutation-Associated and BRCA-Like Solid Tumors.
Front Oncol. 4: 42, 2014.
5)  Lee JM, Ledermann JA, Kohn EC.
PARP Inhibitors for BRCA1/2 mutation-associated and BRCA-like malignancies.
Ann. Oncol. 25: 32-40, 2014.
6)  Hays JL, Kim G, Walker A, Annunziata CM, Lee JM, Squires J, Houston N, Steinberg SM, Kohn EC.
A phase II clinical trial of polyethylene glycol-conjugated L-asparaginase in patients with advanced ovarian cancer: Early closure for safety.
Mol Clin Oncol. 1: 565-569, 2013.
7)  Kohn EC, Romano S, Lee JM.
Clinical implications of using molecular diagnostics for ovarian cancers.
Ann. Oncol. 24 Suppl 10: x22-26, 2013.
Click Here to View Collapsed Bibliography.

This page was last updated on 5/7/2014.